


For the last five years (FY 2020-2024)



Feasibility surveys					
Type	2020	2021	2022	2023	2024
Feasibility Survey for Clinical Trials	11	7	15	4	14
Patient Prevalence Survey	0	2	1	3	1
Reassessment Survey of Ongoing Clinical Trials	1	1	0	0	0
Patient Referral Survey	0	1	1	4	1
Total	12	11	17	11	16

Feasibility survey responses					
	2020	2021	2022	2023	2024
Survey sites	368	476	713	435	678
Responding sites	346	454	691	409	650
Response rates	94.0%	95.4%	96.9%	94.0%	94.6%

Cumulative achievements (FY 2012-)

Number of clinical trials

135 Trials in Total

✓ Ongoing Trials: 50

✓ Completed Trials: 75

✓ Discontinued Trials: 10

Target indications

Pulmonary arterial hypertension

Pediatric neurogenic detrusor overactivity

Hemophilia

Retinopathy of prematurity

Short stature due to growth hormone deficiency

Heart failure

Epilepsy

Spinal Muscular Atrophy (SMA)

Ulcerative colitis

Glioma

Thromboprophylaxis after Fontan surgery

Reflux esophagitis; NSAID-induced ulcer prophylaxis

Mucopolysaccharidosis type II

Prevention of chronic lung disease in extremely premature infants

Juvenile idiopathic arthritis (JIA)

Hyperuricemia

Diabetes mellitus

Constipation

Hepatic encephalopathy

Severe asthma

Atopic dermatitis

Hypercholesterolemia

Hypertension

etc...

Number of approved medicines/devices	
43 Products Approved in Total	
Approved in FY2024 (Apr 2024 – Mar 2025)	Indications (Including label expansions)
Alhemo	Hemophilia (12 years and older)
Nexium	Maintenance therapy for gastroesophageal reflux disease
AZILVA	Hypertension
Tafinlar	Glioma
Mekinist	Glioma

Clinical trials by medical department

Endocrinology	19
Hematology and oncology	17
Gastroenterology	17
Cardiovascular medicine	9
Neurology	6
Allergy	6
Immunology	6
Nephrology	5

※) Long-term extension studies of the same investigational product are excluded.

<Other departments>

Infectious Diseases / Psychiatry / Critical Care Medicine / Neonatology
Plastic Surgery / Clinical Genetics / Neuro-oncology / Anesthesiology etc...